Biotech Values

[NP1986]

Thanks for posting. The overall response rate is fairly low (7%), but it's promising to see a CR with single-agent MEK162. It's in the same ballpark as the response rate seen with AZD6244 (12%).
http://annonc.oxfordjournals.org/content/21/suppl_7/vii345.full

It is somewhat lower than the response rate demonstrated with gemcitabine + cisplatin (26%) in a phase III trial. It would be interesting to see combination trials with MEK162 conducted in biliary tract cancers, but it probably isn't a priority.

Do you know why this particular trial was funded by Array and not by Novartis?